Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAD RO7033877 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Placebo | PLACEBO_COMPARATOR | Saline solution, given as a minimum of a 2 hour infusion |
| Part 1: RO7033877 | EXPERIMENTAL | Single ascending dose |
| Part 2: RO7033877 | EXPERIMENTAL | Single-dose 4-way crossover |
| Name | Type | Description |
|---|---|---|
| Part 1: SAD RO7033877 | DRUG | Single dose |
| Part 1: SAD placebo | DRUG | Single dose |
| Part 2: Treatment A, RO7033877 | DRUG | Single dose RO7033877 and moxifloxacin placebo |
| Part 2: Treatment B, RO7033877 | DRUG | Single dose RO7033877 and moxifloxacin placebo |
| Part 2: Treatment C, moxifloxacin | DRUG | Single dose moxifloxacin and RO7033877 placebo |
| Part 2: Treatment D, RO7033877 and moxifloxacin placebo | DRUG | Single dose moxifloxacin placebo and RO7033877 placebo |
Inclusion Criteria: * Healthy male or female of non-childbearing potential participants, 18 to 65 years of age, inclusive * Healthy status is defined as the absence of evidence of any clinically significant, active, or chronic disease following a detailed medical and surgical history, a complete ph...
SAD RO7033877 is an investigational small molecule developed by Roche Holding AG. It has been studied in a Phase 1 clinical trial in healthy volunteers. The single ascending dose (SAD) designation refers to the first part of a two-part study designed to evaluate safety and tolerability at increasing dose levels.
SAD RO7033877 is made by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the developer responsible for the clinical program. The compound is an investigational agent and has not been approved for any indication.
SAD RO7033877 is in Phase 1 clinical development. It has completed one Phase 1 trial, and no active trials are currently listed. Phase 1 studies primarily assess safety, tolerability, and pharmacokinetics in small groups of participants, often healthy volunteers.
SAD RO7033877 has been evaluated in a single Phase 1 trial, NCT02165332. The study was a two-part, single-dose, randomized, double-blind, placebo-controlled trial that assessed the safety of supra-therapeutic doses of RO7033877 and its effect on the QTc interval. It enrolled 64 healthy volunteers in the United States and is completed.
Yes, SAD RO7033877 is also known as Part 1: SAD RO7033877. The alternative name reflects the single ascending dose portion of the clinical study. Both names refer to the same investigational small molecule developed by Roche Holding AG.